POWER OF INTELLIGENCE

Insight Center: Publications

Freedom to Operate and the Interplay of Patent and Regulatory Exclusivity for Life Sciences (Part II)

Authors: N. Nicole Stakleff and Aparna Nemlekar

2/04/2019
Freedom to Operate and the Interplay of Patent and Regulatory Exclusivity for Life Sciences (Part II)

This article was published on IPWatchdog.com on February 4, 2019. Reproduction in whole prohibited.

While part one of this two-part series on intellectual property (IP) due diligence focused on a life science company’s own IP portfolio, part two will address a company’s understanding of how it fits into the market by considering its freedom to operate, as well as its competitors’, and the interplay of patent and regulatory exclusivity as it relates to the company’s product.

Read Part Two on IPWatchdog.com.

The material in this publication was created as of the date set forth above and is based on laws, court decisions, administrative rulings and congressional materials that existed at that time, and should not be construed as legal advice or legal opinions on specific facts. The information in this publication is not intended to create, and the transmission and receipt of it does not constitute, a lawyer-client relationship.

Data protection laws have changed, so we have revised our Privacy Policy.

CLOSE